Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SEBSP:B1NT34 -0.41%53 3-Year ROIIC % is 3,827.09 as of Dec. 2025, which is 2659% above its 10-year median of 138.70. GuruFocus rates BSP:B1NT34 with a GF Score™ of 53/100 and a GF Value™ of R$27.69 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,322 Biotechnology companies, BioNTech SE ranks better than 98.41% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
BioNTech SE's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 3,827.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BioNTech SE's 3-Year ROIIC % or its related term are showing as below:
BSP:B1NT34's 3-Year ROIIC % is ranked better than 98.41% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs BSP:B1NT34: 3827.09
BioNTech SE (BSP:B1NT34) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BioNTech SE 3-Year ROIIC % Related Terms
BioNTech SE 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for BioNTech SE's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B1NT34 vs INCY, INSM, ROIV: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, BioNTech SE's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BioNTech SE's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
BioNTech SE (BSP:B1NT34) has a 3-Year ROIIC % of 3,827.09 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioNTech SE and its competitors. This is 2659% above median its historical median of 138.70. Over the past decade, BioNTech SE's 3-Year ROIIC % has ranged from 87.46 to 3,827.09. According to the industry distribution chart, BioNTech SE ranks #21 out of 1322 companies in the Biotechnology industry, placing it in the top 1.6%.
Is BioNTech SE's 3-Year ROIIC % too high?
BioNTech SE's current 3-Year ROIIC % of 3,827.09 is 2659% above median its 10-year median of 138.70. Over the past 10 years, this metric has ranged from a low of 87.46 to a high of 3,827.09. Based on the distribution chart, BioNTech SE ranks #21 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioNTech SE has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's 3-Year ROIIC % compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #21 out of 1322 companies for 3-Year ROIIC %. This places BioNTech SE in the top 2% of its industry — outperforming the majority of peers. Historically, BioNTech SE's own 3-Year ROIIC % has ranged from 87.46 to 3,827.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioNTech SE and its competitors. BioNTech SE's current 3-Year ROIIC % is 3,827.09, which is 2659% above median its own 10-year median of 138.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$27.69, compared to a current price of R$28.83 — trading 4.1% above its estimated fair value. The current 3-Year ROIIC % is 3,827.09, which is 2659% above median its 10-year median of 138.70. BioNTech SE's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current 3-Year ROIIC % is 3,827.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$28.83 is trading 4.1% above its estimated GF Value™ of R$27.69.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BSP:B1NT34:
3-Year ROIIC %: 3,827.09 (2659% above median its 10-year median of 138.70)
GF Value™: R$27.69 vs. price of R$28.83 (4.1% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
53GF Score
Get the complete analysis for BSP:B1NT34
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
